Detailed data on Alnylam’s heart drug show substantial benefit, while competition likely awaits

Taking stock of the drug industry, from the lab to the medicine chest

August 30, 2024 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Adobe STAT+ | Detailed data on Alnylam's heart drug show substantial benefit, while competition likely awaits The results likely clear the drug's path to approval, but it could still face competition from another treatment being developed by BridgeBio. By Andrew Joseph STAT+ | New Wegovy analysis could boost Novo Nordisk's bid to expand drug's label in heart failure Researchers say the drug cut the risk of severe complications in patients with a common form of heart failure known as HFpEF. By Elaine Chen STAT+ | Wegovy cut patients' chances of dying from Covid-19, new analysis shows Compared to placebo, the weight loss drug developed by Novo Nordisk cut the chances of dying from the disease by roughly a third. By Andrew Joseph

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2024, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser